Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
As of close of business last night, Sana Biotechnology Inc’s stock clocked out at $1.75, up 2.05% from its previous closing price of $1.71. In other words, the price has increased by $2.05 from its previous closing price. On the day, 1.27 million shares were traded.
Ratios:
To gain a deeper understanding of SANA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.40 and its Current Ratio is at 3.40. In the meantime, Its Debt-to-Equity ratio is 0.44 whereas as Long-Term Debt/Eq ratio is at 0.37.
On March 14, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $7.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 18 ’25 when CHRISTIAN HORDO & KATHARINE HO bought 75,000 shares for $3.16 per share.
CHRISTIAN HORDO & KATHARINE HO bought 75,000 shares of SANA for $289,500 on Jan 16 ’25. On Jan 08 ’25, another insider, FMR LLC, who serves as The insider 1 of the company, sold 290,912 shares for $6.49 each. As a result, the insider received 1,887,320 and left with 4,541,511 shares of the company.
Stock Price History:
Over the past 52 weeks, SANA has reached a high of $9.49, while it has fallen to a 52-week low of $1.26. The 50-Day Moving Average of the stock is -9.14%, while the 200-Day Moving Average is calculated to be -44.45%.
Shares Statistics:
A total of 225.46M shares are outstanding, with a floating share count of 125.44M. Insiders hold about 44.39% of the company’s shares, while institutions hold 51.55% stake in the company.
Earnings Estimates
Sana Biotechnology Inc (SANA) is presently subject to a detailed evaluation by 1.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.1 and low estimates of -$0.1.
Analysts are recommending an EPS of between -$0.59 and -$0.8 for the fiscal current year, implying an average EPS of -$0.69. EPS for the following year is -$0.72, with 3.0 analysts recommending between -$0.57 and -$0.91.
